NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Up 55.9% in December

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 132,400 shares, a growth of 55.9% from the November 30th total of 84,900 shares. Based on an average daily trading volume, of 370,600 shares, the days-to-cover ratio is presently 0.4 days. Approximately 8.1% of the shares of the company are sold short.

Hedge Funds Weigh In On NLS Pharmaceutics

An institutional investor recently raised its position in NLS Pharmaceutics stock. Armistice Capital LLC boosted its holdings in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) by 6.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,311,000 shares of the company’s stock after buying an additional 139,000 shares during the period. Armistice Capital LLC owned approximately 19.62% of NLS Pharmaceutics worth $501,000 as of its most recent SEC filing.

NLS Pharmaceutics Trading Down 2.2 %

Shares of NLSP opened at $1.82 on Friday. NLS Pharmaceutics has a one year low of $1.73 and a one year high of $24.34. The company’s fifty day moving average price is $3.12 and its 200 day moving average price is $1.73.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).